Guillaume Arcile1
1Institut de Chimie des Substances Naturelles ICSN-CNRS, France
Title: Neuroprotective effect of SNC-1, a biocatalysis processed ayurvedic plant extract as a promising ethnopharmaceutic treatment for Alzheimer’s and Parkinson’s disease
Biography
Biography: Guillaume Arcile1
Abstract
The three ayurvedic medicinal plants Withania somnifera, Emblica officinalis, and Bacopa monnieri, were extracted by high-pressure
static extraction using the Zippertex technology. The extracts were mixed to reach quantifiable amounts of active compounds
identified by HPLC-MS analysis. The mixture of extracts was incubated with resting cells of the fungus Beauveria bassiana ATCC
7159. The fermentation promoted the fluidization of the starting dense mixture, while HPLC monitoring evidenced the disappearance
of glucogallin from E. officinalis extract and the concomitant increase in Gallic acid content. While topical exposure of the chick
embryo chorioallantoic membrane (CAM) to the non-fermented extract led to an extensive necrosis, the fermented extract was
not toxic and reduced the CAM vascularization, supporting its antiangiogenic potency. The innocuity of the fermented extract was
demonstrated using the in vivo LD50 test, the morphological examination of internal organs of treated rats, as well as the evaluation
of blood biomarkers of liver damage (aspartate aminotransferase and alanine aminotransferase). The fermented extract SNC-1 was
developed as a nutraceutical antiangiogenic treatment of age-related macular degeneration and commercialized in an oral form
named Ethnodyne-Visio. Furthermore, study showed that SNC-1 (dried from of Ethnodyne-Visio) was able to significantly protect
neurons (cortical as well as dopaminergic neurons – in vitro models of Alzheimer’s and Parkinson’s diseases) from different injuries
(β amyloid, mitochondrial toxins, glutamate). Additionally, SNC-1 stimulated neurite outgrowth). Interestingly these effects were still
observed at low doses and were still efficient when the extract was applied up to 4h after the toxins application. Extensive efforts are
dedicated to the identification of the active compound responsible of these effects. Clinical trials are underway to confirm the benefit
of SNC-1 for Alzheimer and Parkinson patients.
Guillaume.ARCILE@cnrs.fr